摘要
目的探索阿立哌唑治疗Tourette综合征共患注意缺陷多动障碍患儿的疗效及安全性。方法选择Tourette综合征共患注意缺陷多动障碍患儿44例,随机分为阿立哌唑组和氟哌啶醇组,分别给予阿立哌唑和氟哌啶醇治疗12周,治疗前后采用耶鲁综合抽动严重程度量表(Yale global tic severity scale,YGTSS)和Conners(父母)症状问卷提供的多动指数标准评估患儿抽动症状及多动指数改善情况,并记录治疗过程中发生的药物副反应。结果重复测量方差分析示,对于YGTSS评分,分组主效应无统计学意义(P>0.05),时间主效应、分组与时间的交互效应有统计学意义(P<0.05);对于多动指数,分组主效应、时间主效应、分组与时间的交互效应均有统计学意义(P<0.05)。治疗12周时,两组YGTSS评分无统计学差异(P>0.05),阿立哌唑组多动指数低于氟哌啶醇组(P<0.01)。阿立哌唑组出现副反应者(3/22)比氟哌啶醇组(6/22)少(P<0.05)。结论阿立哌唑治疗Tourette综合征共患注意缺陷多动障碍患儿的抽动症状与氟哌啶醇相当,且可一定程度减轻其多动、注意力缺陷等症状,副作用较氟哌啶醇少。
ObjectiveTo evaluate the efficacy and safety of aripiprazole treatment for co-morbid attention deficiency hyperactivity disorder（ADHD） in children with Tourette syndrome（TS）.MethodsForty four TS children with co-morbid ADHD were randomly divided into aripiprazole group and haloperidol group. The aripiprazole group and haloperidol group received aripiprazole and haloperidol treatment for 12 weeks, respectively. Yale global tic severity scale（YGTSS） and Conners parent symptom questionnaire（PSQ） were used to assess the tic and ADHD symptoms before, 2, 4,8 and 12 weeks after treatment. Side effects were recorded weekly.ResultsRepeated measure ANOVA indicated that the main effects of groups was not significant to the YGTSS scores（P0.05）, but significant to the PSQ scores（P0.05）.After 12-week treatment, the YGTSS scores between two groups were not significantly different（P0.05）. The PSQ scores of aripiprazole group were significantly lower than that of haloperidol group. The adverse reactions of aripiprazole group were milder compared with the haloperidol group（P0.05）.ConclusionsThe present study demonstrates that aripiprazole has the same efficacy in the treatment of tics as haloperidol, improves co-morbid ADHD symptoms, and its adverse reactions are much less compared with haloperidol.
出处
《中国神经精神疾病杂志》
CAS
CSCD
北大核心
2016年第3期156-160,共5页
Chinese Journal of Nervous and Mental Diseases
